Peptomyc is a Barcelona-based biotech company , spin-off of Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institution for Research and Advanced Studies (ICREA). Specialising in a groundbreaking approach to one of oncology’s greatest challenges, it develops novel cell-penetrating mini-protein therapeutics that directly inhibit the oncoprotein MYC — a central driver of tumour proliferation, survival and resistance.

At the core of Peptomyc’s mission is its lead candidate, OMO-103, the first-in-class mini-protein inhibitor of MYC. In early clinical trials, OMO-103 has demonstrated a favourable safety profile and initial signs of anti-tumour activity across heavily pre-treated patients with advanced solid tumours. With this milestone achieved, Peptomyc is accelerating into Phase II, exploring OMO-103 in advanced osteosarcoma and other high-unmet-need indications.

Peptomyc’s proprietary platform harnesses 20 + years of pioneering research, combining patented mini-protein design with robust cell-penetrating domains that deliver therapeutic payloads directly to the nucleus of cancer cells — thereby addressing the historic “undruggable” nature of MYC.